Urinary Acidifier and Crystallization Inhibitor Combination for Kidney Stone Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for urine acidification, such as using substances like ammonium chloride or berries, lose effectiveness over time, and existing crystallization inhibitors like citrate are not suitable for patients with renal tubular acidosis, making it difficult to prevent calcium phosphate supersaturation and kidney stone formation.
Innovation Solution
A combination of urinary acidifiers and calcium phosphate crystallization inhibitors, such as phytic acid, is used to synergistically increase the time for calcium phosphate precipitation, preventing stone formation by simultaneously or sequentially administering these compounds in a medicament.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If urinary acidifiers like ammonium chloride or arginine are used continuously, then urine pH is reduced, but they lose effectiveness over time
Solution Approach 1:
The patent combines urinary acidifiers (ammonium chloride, arginine) with crystallization inhibitors (citrate, phytate) into a single composition. This merging allows the acidifier to reduce urine pH while the inhibitor maintains crystallization prevention, compensating for the acidifier's diminishing effectiveness over time and providing sustained protection against calcium phosphate stones.
Solution Approach 2:
The invention uses composite formulations containing multiple active ingredients with complementary mechanisms of action. The acidifying agents work synergistically with crystallization inhibitors to achieve both pH reduction and stone prevention, creating a more reliable and durable therapeutic effect than single-agent treatments.
2Reliability
If citrate is used as a crystallization inhibitor, then calcium phosphate crystallization is inhibited, but it is not suitable for patients with renal tubular acidosis
Solution Approach 1:
The patent develops a multi-functional composition that addresses both crystallization inhibition and urine acidification needs. By including multiple acidifiers (ammonium chloride, arginine, cysteine) alongside crystallization inhibitors, the formulation becomes universally applicable to different patient conditions, including those with renal tubular acidosis who cannot tolerate citrate alone.
Solution Approach 2:
The invention changes the compositional parameters by incorporating multiple types of acidifiers with different mechanisms and profiles. This allows customization and adaptation for patients with renal tubular acidosis, providing alternative acidifying agents that do not depend on citrate metabolism, thereby expanding the therapeutic适用范围.
3Reliability
If urine pH is maintained above 6.2, then calcium phosphate supersaturation occurs, but acidification procedures fail in patients with renal tubular acidosis
Solution Approach 1:
The patent merges acidification procedures with crystallization inhibition therapy into a single integrated treatment. The composition contains both acidifiers to lower urine pH and crystallization inhibitors to prevent supersaturation, making the treatment more effective and easier to administer, especially for renal tubular acidosis patients who cannot respond to acidification alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly increases the inhibitory capacity of crystallization inhibitors when urine pH is decreased, effectively delaying calcium phosphate precipitation and reducing the risk of kidney stones.
Implementation Method 1
substances such as ammonium chloride or arginine, in amounts on the order of 1 g/day, are able to reduce urinary pH values. This is because they act as carriers of hydrogen ions to the nephron, where they are released and thereby acidify the urine
Implementation Method 2
several substances with this capability have been described among which it is worth noting citrate, pyrophosphate and phytate. the ionic species of phytic acid (phytates) have the capacity to inhibit the development of calcium salts in biological fluids, decreasing the risk of both developing calcium kidney stones
Implementation Method 3
The combination of these two types of compounds produces a synergistic effect, which is able to increase the time it takes for calcium phosphate to precipitate, the first stage in the formation of kidney stones
Data Source
AI summary
The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.